NLTX - Neoleukin Therapeutics Inc Stock Price, Fair Value and News

$15.10

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NLTX Price Action

NLTX RSI Chart

NLTX Valuation

Market Cap

204.4M

Price/Earnings (Trailing)

-3.04

Price/Sales (Trailing)

8.18

EV/EBITDA

-4.26

Price/Free Cashflow

-2.44

NLTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NLTX Fundamentals

NLTX Revenue

Revenue (TTM)

25.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

NLTX Earnings

Earnings (TTM)

-53.2M

Earnings Growth (Yr)

-38.69%

Earnings Growth (Qtr)

-9.33%

NLTX Profitability

EBT Margin

-136.30%

Return on Equity

-38.75%

Return on Assets

-32.44%

Free Cashflow Yield

-40.92%

NLTX Investor Care

Shares Dilution (1Y)

58.06%

Diluted EPS (TTM)

70.22

NLTX Alerts

JANUS HENDERSON GROUP PLC reported owning 5.5% of NLTX [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2018	0	0	0	25.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Neoleukin Therapeutics Inc

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

CEO	Ms. Donna M. Cochener-Metcalfe J.D.
WEBSITE	neoleukin.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	7

Neoleukin Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Neoleukin Therapeutics Inc? What does NLTX stand for in stocks?

NLTX is the stock ticker symbol of Neoleukin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neoleukin Therapeutics Inc (NLTX)?

As of Thu Oct 31 2024, market cap of Neoleukin Therapeutics Inc is 204.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NLTX stock?

You can check NLTX's fair value in chart for subscribers.

Is Neoleukin Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NLTX is over valued or under valued. Whether Neoleukin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Neoleukin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NLTX.

What is Neoleukin Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 31 2024, NLTX's PE ratio (Price to Earnings) is -3.04 and Price to Sales (PS) ratio is 8.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NLTX PE ratio will change depending on the future growth rate expectations of investors.